JP2024523838A5 - - Google Patents
Info
- Publication number
- JP2024523838A5 JP2024523838A5 JP2023575788A JP2023575788A JP2024523838A5 JP 2024523838 A5 JP2024523838 A5 JP 2024523838A5 JP 2023575788 A JP2023575788 A JP 2023575788A JP 2023575788 A JP2023575788 A JP 2023575788A JP 2024523838 A5 JP2024523838 A5 JP 2024523838A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cdr
- antigen
- sequence number
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/099228 | 2021-06-09 | ||
| CN2021099228 | 2021-06-09 | ||
| PCT/CN2022/097889 WO2022258015A1 (en) | 2021-06-09 | 2022-06-09 | Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523838A JP2024523838A (ja) | 2024-07-02 |
| JP2024523838A5 true JP2024523838A5 (https=) | 2025-06-18 |
Family
ID=84425689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575788A Pending JP2024523838A (ja) | 2021-06-09 | 2022-06-09 | Ｏｘ４０及び／又はｐｄ－ｌ１に結合する抗体及び二重特異性結合タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250282881A1 (https=) |
| EP (1) | EP4352108A4 (https=) |
| JP (1) | JP2024523838A (https=) |
| KR (1) | KR20240019797A (https=) |
| CN (1) | CN117529503A (https=) |
| AU (1) | AU2022288037A1 (https=) |
| CA (1) | CA3221866A1 (https=) |
| IL (1) | IL308918A (https=) |
| TW (1) | TW202315893A (https=) |
| WO (1) | WO2022258015A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2973548T3 (es) * | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| CN110337448B (zh) * | 2016-12-23 | 2023-08-08 | 瑞美德生物医药科技有限公司 | 使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法 |
| US20200157224A1 (en) * | 2017-06-25 | 2020-05-21 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
| CN111315405A (zh) * | 2017-11-09 | 2020-06-19 | 免疫医疗有限责任公司 | 双特异性融合多肽及其使用方法 |
| AU2018394939B2 (en) * | 2017-12-29 | 2022-02-24 | Ap Biosciences, Inc. | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy |
| CN110305210B (zh) * | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| US10597453B2 (en) * | 2018-06-29 | 2020-03-24 | Gensun Biopharma, Inc. | Antitumor immune checkpoint regulator antagonists |
| JP7575100B2 (ja) * | 2018-11-13 | 2024-10-29 | ジェイエヌ バイオサイエンシーズ エルエルシー | 免疫細胞活性化のための二重特異性抗体 |
| US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
| TWI793395B (zh) * | 2019-01-25 | 2023-02-21 | 大陸商信達生物製藥（蘇州）有限公司 | 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體 |
| CN110003338B (zh) * | 2019-04-16 | 2021-04-23 | 北京免疫方舟医药科技有限公司 | 抗ox40抗体及其应用 |
| CN114746451A (zh) * | 2019-11-27 | 2022-07-12 | 上海岸迈生物科技有限公司 | TGFβ/PD-L1双特异性结合蛋白 |
-
2022
- 2022-06-09 IL IL308918A patent/IL308918A/en unknown
- 2022-06-09 CA CA3221866A patent/CA3221866A1/en active Pending
- 2022-06-09 EP EP22819612.7A patent/EP4352108A4/en active Pending
- 2022-06-09 AU AU2022288037A patent/AU2022288037A1/en active Pending
- 2022-06-09 TW TW111121529A patent/TW202315893A/zh unknown
- 2022-06-09 KR KR1020247000219A patent/KR20240019797A/ko active Pending
- 2022-06-09 WO PCT/CN2022/097889 patent/WO2022258015A1/en not_active Ceased
- 2022-06-09 US US18/568,252 patent/US20250282881A1/en active Pending
- 2022-06-09 CN CN202280040981.5A patent/CN117529503A/zh active Pending
- 2022-06-09 JP JP2023575788A patent/JP2024523838A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7790754B2 (ja) | Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用 | |
| US11746148B2 (en) | Antibody molecules comprising a single-domain antigen-binding site and Fab fragments | |
| CN109983033B (zh) | 调节细胞表达的生物活性的结合分子 | |
| TWI802633B (zh) | 針對pd-1之單域抗體及其變異體 | |
| TWI701259B (zh) | ４﹘１ｂｂ抗體及其製備方法和應用 | |
| JP2024050684A (ja) | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ | |
| TW202430563A (zh) | 抗cd38抗體及其使用方法 | |
| US20200216540A1 (en) | Antibodies that modulate a biological activity expressed by a cell | |
| WO2017059387A1 (en) | Binding molecules with modified j-chain | |
| AU2020363041B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| WO2019184909A1 (zh) | 新型抗体分子、其制备方法及其用途 | |
| JP2024523838A5 (https=) | ||
| CA3068932A1 (en) | Bispecific anti pd1-anti tim3 antibodies | |
| CA3207791A1 (en) | Anti-cd112r antibody and use thereof | |
| CN115260312A (zh) | 结合ox40的抗体或抗原结合片段 | |
| WO2022258015A1 (en) | Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1 | |
| CN119894930A (zh) | 一种双特异性抗体及其应用 | |
| JP7570653B2 (ja) | ヒト化抗体、キメラ抗原受容体、核酸、ベクター、細胞及び応用 | |
| RU2839380C1 (ru) | Fc-оптимизированные антитела к cd25 для истощения опухолеспецифических клеток | |
| RU2779128C2 (ru) | Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение | |
| HK40082471A (en) | Binding protein having h2l2 and hcab structures | |
| JP2025503446A (ja) | Ｔｉｇｉｔ抗体及びその用途 | |
| CN116323658A (zh) | 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途 | |
| EA051900B1 (ru) | Антитела против cd112r и варианты их применения | |
| WO2020150282A1 (en) | Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis |